Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/145822
Speakers Corinne Solier, Ph.D. Leader, Clinical Protein Biomarkers Roche Stacey House, M.D. Division of Emergency Medicine, Washington University in St. Louis School of Medicine Ultrasensitive Immunoassays for Translation of Biomarkers from Discovery to the Clinic Webinars Free Registration! www.GENengnews.com/biomarkers Lynn R. Zieske, Ph.D. Vice President Commercial Solutions Singulex Translating basic research into the clinic requires simple, fast, and cost-efective technologies for biomarker screening and identi- What You Will Learn n How Erenna technology can improve the sensitivity over conventional ELISA assays by up to three orders of magnitude n How Erenna technology can improve quantifcation of critical low abundance analytes n How the Erenna System enables high sensitivity assays, such as cytokine assays, in various matrices n How ultrasensitive high defnition immunoassays can translate biomarkers into a clinical setting n How the Erenna System enables fexible and fast assay development n How Erenna assays allow low volume consumption enabling multiple measurements fcation from disease characterization to drug development. Singulex' proprietary single-molecule counting immunoassay technology helps overcome challenges in the translation of protein Moderator biomarkers to the clinic. Its improved precision has enabled the measurement of endogenous biomarker concentrations at femtogram levels and precise monitoring over time. The Singulex Erenna platform uses paramagnetic microparticles as the solid-phase support for immune capture and a digital counting system that detects single molecules as they pass through an interrogation space via capillary fow. This detection system results in a John Sterling Editor in Chief GEN count of discreet detection events above background rather than a sum of total fuorescence including background. In the webinar, participants will discuss the use of Erenna technology in serial testing of the cardiac biomarker troponin I (cTnI), DATE the standard of care for patients under evaluation for acute coro- View it Now On Demand discussed will be the comparative performance of the Singulex 60 minutes IL-17A research use only Assay to conventional assays for detection COST of this biomarker in rheumatoid arthritis patients and the validation Complimentary of this platform for use in clinical trials. n Biomarker researchers and developers n Drug developers n Immunologists n Researchers interested in advances in immunoassay technologies nary syndromes and now employed for the monitoring of chronic DURATION Who Should Attend cardiovascular disease by the Singulex Clinical Laboratory. Also Produced with support from